The problem: Roughly 90% of cancer drugs that enter clinical trials never reach patients. The most common reason isn't the science, it's the funding structure. Single-trial financing is fragile. One failure ends everything.

The solution: CanceRx uses long-duration bond structures to finance diversified portfolios of oncology clinical trials. The same risk-distribution logic that makes bond markets work, applied to the most important R&D pipeline in medicine.
By spreading capital across multiple trials in parallel, we reduce the binary risk that kills promising therapies before they reach patients. Institutional investors get a new asset class with durable, uncorrelated returns. Researchers get the runway to see their science through.

CanceRx

Org chart

Teams

Offices